Sickle cell disease causes accelerated kidney function decline, yet proven GFR-preserving therapies remain elusive. In this study of adults with sickle cell disease, RASi use was not associated with a significant difference in the rate of eGFR decline.
Mais episódios de "Kidney360"



Não percas um episódio de “Kidney360” e subscrevê-lo na aplicação GetPodcast.








